AD(ing) an antagonist

Otsuka jumps to Phase III in Alzheimer's with Lundbeck deal

Otsuka Pharmaceutical Co. Ltd.'s deal with H. Lundbeck A/S gives the Japanese pharma a piece of the most advanced serotonin (5-HT6) receptor antagonist to treat the cognitive symptoms of Alzheimer's disease. The partners expect to start a Phase III trial of the molecule - Lu AE58054 - this year.

The March deal is part of a 2011 neurology alliance between Lundbeck and Otsuka to co-develop and co-commercialize up to five products. Lu AE58054 is the first Lundbeck compound and the third compound overall to be

Read the full 842 word article

How to gain access

Continue reading with a
two-week free trial.